ANABV
AnaptysBio, Inc. Common Stock When IssuedNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.41
52W High
$49.76
52W Low
$41.99
50-Day MA
$44.84
200-Day MA
$44.84
Dividend Yield
—
Profit Margin
-5.64%
Forward P/E
—
PEG Ratio
—
About AnaptysBio, Inc. Common Stock When Issued
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of severe diseases. The company's proprietary platform leverages its unparalleled ability to create high-quality, diverse monoclonal antibodies aimed at addressing unmet medical needs, primarily in immunology and oncology. AnaptysBio's innovative candidates, which include various therapeutic antibodies currently in clinical trials, highlight its commitment to advancing the science of antibody-based therapies. With a robust pipeline and strategic partnerships, the company aims to deliver transformative treatments that improve patient outcomes.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | 0 |
| Float | $17.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 5/5/2026